
Anti-amyloid antibodies slow early Alzheimer's decline ~30%, with modest benefit and risks
Louis shares a JAMA perspective noting that lecanemab and donanemab clear brain amyloid and slow cognitive decline by roughly 30% in early disease, supporting a causal role for amyloid. The effects remain modest and are limited by amyloid-related imaging abnormalities.
